Covaxine
- All
- News
-
Top Medical Body Slams Study On Covaxin Safety, Side-Effects, Wants Apology
The Indian Council of Medical Research, or ICMR, has distanced itself from a follow-up study by two Banaras Hindu University professors that said nearly a third of 926 individuals who got the India-made Covaxin shot reported serious side-effects.
-
Fact Check: Can Covaxin Lead To Death After 2 Years Of Vaccination?
As per a social media user, Covaxin COVID vaccine can cause death after two years of vaccination. The user also claims that the Covaxin has caused the deaths of crores of people. We did the fact check and it came out to be false.
-
Covaxin Has Excellent Safety Record: Bharat Biotech On Study Citing Risks
The study, led by Banaras Hindu University (BHU), claimed that Covaxin raised the rare risk of stroke, and Guillain-Barre syndrome, among others.
-
Over 30% Covaxin Takers Suffered Health Issues After A Year, Claims Study
Nearly one-third of the individuals who received Bharat Biotech's anti-Covid vaccine Covaxin reported 'adverse events of special interest,' or AESI, according to a one-year follow-up study conducted at BHU.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
No Side Effects From Our Vaccine: Covaxin Maker Amid AstraZeneca Row
The Covaxin was developed with a single-minded focus on safety first, said its maker Bharat Biotech on Thursday, days after British pharma giant AstraZeneca admitted that its Covid vaccine can cause rare side effects.
-
Top Medical Body ICMR's Study Indicates Covaxin Booster Dose Safe: Centre
An ICMR study has indicated that a booster dose of Covaxin is safe and necessary to ensure persistent immunity to minimise breakthrough infections of COVID-19, Minister of State for Health Bharati Pravin Pawar informed Parliament on Friday.
-
No External Pressure To Accelerate Development Of Covaxin: Bharat Biotech
Covid-19 vaccine Covaxin maker Bharat Biotech today said there was no external pressure on the firm to speed up its development.
-
Government Rubbishes Reports On Approval For Covaxin Due To Political Pressure
The Union Health Ministry today termed as "misleading" and "fallacious" media reports which claimed that regulatory approval for COVID-19 vaccine Covaxin was rushed due to political pressure.
-
50 Million Doses Of Covaxin Set To Expire Early 2023: Report
Nearly 50 million doses of Bharat Biotech's COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said.
-
Corbevax Approved As Booster Dose For Adults Vaccinated With Covaxin, Covishield
The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.
-
Japan Approves Covaxin Booster Dose For Travellers: Bharat Biotech
Bharat Biotech on Friday said Japan has approved Covaxin booster dosage for travellers visiting the country.
-
"Covaxin Safe For Kids Aged 2-18": Here's What Bharat Biotech Says On Side-Effects
Data on Covaxin for children has been published online in The Lancet Infectious Diseases journal on June 16
-
Covaxin Booster Enhances Efficacy Against Delta, Omicron Variants: Study
The administration of Covaxin as a booster dose enhances vaccine effectiveness against COVID-19's Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found.
-
US Health Regulator Lifts Hold On Covaxin's Clinical Trials
The US Food and Drug Administration which has put on hold phase 2/ 3 clinical trials of Bharat Biotech's COVID-19 vaccine Covaxin, in USA, has lifted pause, according to a statement issued by Ocugen Inc, Bharat Biotech's partner for jab in US, Canada
-
Top Medical Body Slams Study On Covaxin Safety, Side-Effects, Wants Apology
The Indian Council of Medical Research, or ICMR, has distanced itself from a follow-up study by two Banaras Hindu University professors that said nearly a third of 926 individuals who got the India-made Covaxin shot reported serious side-effects.
-
Fact Check: Can Covaxin Lead To Death After 2 Years Of Vaccination?
As per a social media user, Covaxin COVID vaccine can cause death after two years of vaccination. The user also claims that the Covaxin has caused the deaths of crores of people. We did the fact check and it came out to be false.
-
Covaxin Has Excellent Safety Record: Bharat Biotech On Study Citing Risks
The study, led by Banaras Hindu University (BHU), claimed that Covaxin raised the rare risk of stroke, and Guillain-Barre syndrome, among others.
-
Over 30% Covaxin Takers Suffered Health Issues After A Year, Claims Study
Nearly one-third of the individuals who received Bharat Biotech's anti-Covid vaccine Covaxin reported 'adverse events of special interest,' or AESI, according to a one-year follow-up study conducted at BHU.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
No Side Effects From Our Vaccine: Covaxin Maker Amid AstraZeneca Row
The Covaxin was developed with a single-minded focus on safety first, said its maker Bharat Biotech on Thursday, days after British pharma giant AstraZeneca admitted that its Covid vaccine can cause rare side effects.
-
Top Medical Body ICMR's Study Indicates Covaxin Booster Dose Safe: Centre
An ICMR study has indicated that a booster dose of Covaxin is safe and necessary to ensure persistent immunity to minimise breakthrough infections of COVID-19, Minister of State for Health Bharati Pravin Pawar informed Parliament on Friday.
-
No External Pressure To Accelerate Development Of Covaxin: Bharat Biotech
Covid-19 vaccine Covaxin maker Bharat Biotech today said there was no external pressure on the firm to speed up its development.
-
Government Rubbishes Reports On Approval For Covaxin Due To Political Pressure
The Union Health Ministry today termed as "misleading" and "fallacious" media reports which claimed that regulatory approval for COVID-19 vaccine Covaxin was rushed due to political pressure.
-
50 Million Doses Of Covaxin Set To Expire Early 2023: Report
Nearly 50 million doses of Bharat Biotech's COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said.
-
Corbevax Approved As Booster Dose For Adults Vaccinated With Covaxin, Covishield
The government on Wednesday approved Biological E's Corbevax as a precaution dose for those above 18 years fully vaccinated with either Covishield or Covaxin.
-
Japan Approves Covaxin Booster Dose For Travellers: Bharat Biotech
Bharat Biotech on Friday said Japan has approved Covaxin booster dosage for travellers visiting the country.
-
"Covaxin Safe For Kids Aged 2-18": Here's What Bharat Biotech Says On Side-Effects
Data on Covaxin for children has been published online in The Lancet Infectious Diseases journal on June 16
-
Covaxin Booster Enhances Efficacy Against Delta, Omicron Variants: Study
The administration of Covaxin as a booster dose enhances vaccine effectiveness against COVID-19's Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found.
-
US Health Regulator Lifts Hold On Covaxin's Clinical Trials
The US Food and Drug Administration which has put on hold phase 2/ 3 clinical trials of Bharat Biotech's COVID-19 vaccine Covaxin, in USA, has lifted pause, according to a statement issued by Ocugen Inc, Bharat Biotech's partner for jab in US, Canada
